A rather disappointing paper. First, the full paper is, as so often, behind a paywall.
Also, because the the paper doesn't come out with a clear "Yes, the tests are wonderful and reliable."
It is quite clear that there is sufficient uncertainty to question all results from these tests.
We have had a few posts recently mentioning TSH receptor antibodies and/or TSI - so likely to be of some interest.
US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease
The Journal of Clinical Endocrinology & Metabolism, dgae448, doi.org/10.1210/clinem/dgae448
Published: 19 July 2024
Abstract
Context
Bioassays provide information on the functionality of thyrotropin receptor antibodies (TSH-R-Ab) and thus may offer more clinical utility than binding assays.
Objective
In this prospective, blinded, US-based study, the clinical performance of several TSH-R-Ab assays was compared.
Setting
US endocrinology clinic.
Subjects
One hundred sixty-two unselected, consecutive, well-documented patients with various thyroid diseases and healthy controls.
Intervention(s)
Blinded TSH-R-Ab measurements.
Main Outcome Measure(s)
Sensitivity and specificity of 4 TSH-R-Ab assays.
Results
The 4 TSH-R-Ab assays were negative in all 42 patients without autoimmune thyroid disease (AITD). In 104 patients with Graves’ disease (GD), irrespective of the disease duration, TSH-R-Ab positivity was present in 65 (63%), 67 (65%), and 87 (84%) for the Cobas and Immulite binding assays and stimulatory TSH-R-Ab [thyroid-stimulating immunoglobin (TSI)] bioassay, respectively (TSI vs Immulite P < .0025, TSI vs Cobas P < .0009). Fifteen newly diagnosed GD patients were all positive in the TSI bioassay, but only 11 (73%) were positive in the Cobas and Immulite binding assays. Nine GD patients with biochemical subclinical hyperthyroidism were TSI-positive but Immulite- and Cobas-negative. Two GD patients were blocking TSH-R-Ab [thyroid-blocking immunoglobin (TBI)]-positive and TSI-negative, and the Immulite and Cobas were positive in both. Additional serum samples from AITD patients that consisted of 30 TBI-positive and 10 TSI-positive samples were blindly tested in the binding assays. Only 6 of the 10 TSI-positive samples were positive in both binding assays, and 30 and 28 of the TBI-positive samples were positive in the Cobas and Immulite assays, respectively.
Conclusion
Binding TSH-R-Ab assays are less sensitive than TSI bioassays and are not specific for stimulating antibodies. Measuring the function of TSH-R-Ab in a bioassay can provide useful information to clinicians.
Keywords: thyrotropin receptor antibody, binding assay, bioassay, autoimmune thyroid disease
Paper is behind a paywall - only this abstract is accessible: